Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.

Yuqing ZhangCourtney W HouchenMin Li

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296.

Keyphrases

high throughput
single cell
healthcare
palliative care
locally advanced
quality improvement
drug induced
squamous cell carcinoma
affordable care act
single molecule
radiation therapy
rectal cancer
induced pluripotent stem cells
health insurance